Answers are grounded in this paper and cite their sources.
PURPOSE: This study aimed to explore the clinical factors associated with response in patients receiving ketamine, evaluating changes in suicidality in each treatment session and the side effects of ketamine infusion therapy for depression. METHODS: A retrospective descriptive study was conducted using electronic medical records from 90 patients treated with subanesthetic ketamine infusions between 2019 and 2023. Depression and suicidality scores were measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Clinical response was defined as a 50% or greater reduction in MADRS score at the final treatment session. The primary outcome was clinical factors associated with response in patients treated with ketamine. RESULTS: Of the 90 patients, 35 were classified as responders. Logistic regression analysis identified baseline suicidality scores on MADRS (adjusted OR: 1.46, P=0.019) and comorbid anxiety disorder (adjusted OR: 4.39, P=0.048) as significantly associated with treatment response. Generalized estimating equation analysis revealed that each additional ketamine session was associated with a significant reduction in MADRS (coefficient =-1.11, P<0.001) and suicidality scores (coefficient =-0.14, P<0.001). Side effects occurred more frequently in nonresponders. CONCLUSIONS: These findings suggest that baseline suicidality and comorbid anxiety disorders are important factors to consider when selecting candidates for ketamine therapy. Future research should aim to further elucidate the factors contributing to the efficacy and safety of ketamine as a treatment for depression.
No takes yet. Share an insight, caveat, or question.
Vichitkunakorn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: